KR Choksey maintains a BUY rating on Rossari Biotech with a target price of Rs 1,034, reflecting a 31.4% upside from the current market price of Rs 787. Despite lower-than-expected Q2FY25 results due to challenges in the HPPC and TSC segments, the company showed year-on-year growth in revenue, gross profit, EBITDA, and PAT, driven by strong export performance. Adjustments to FY25E/FY26E EPS estimates have been made, but long-term growth potential remains positive with expected capacity additions in the specialty chemicals sector.